Clarix Imaging

Executive Summary

Clarix Imaging is a private medical device company headquartered in San Francisco, developing advanced imaging solutions for surgical oncology. Its flagship product, the VSI-360™, is an FDA-cleared intraoperative volumetric specimen imaging system that provides real-time 3D visualization of excised tissue, initially targeting breast cancer lumpectomy procedures. The system aims to enhance surgical precision by enabling clear visualization of tumor margins, potentially reducing re-excision rates and improving patient outcomes. Founded in 2017, the company is positioned in the diagnostics market with a commercial product already cleared by the FDA, suggesting it has reached an early commercialization phase. However, detailed financials, employee count, and funding history are not publicly available, indicating a relatively low profile in the investment community. Given the growing emphasis on precision oncology and intraoperative decision-making, Clarix Imaging's technology addresses a clear clinical need. The VSI-360 has the potential to expand beyond breast cancer into other solid tumors, such as skin, lung, or colorectal cancers, which would broaden its addressable market. The company's private status and limited public disclosures suggest that key catalysts may revolve around clinical evidence generation, strategic partnerships, or additional regulatory clearances. While the lack of public data introduces uncertainty, the FDA clearance provides a baseline for credibility and commercial traction.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for additional cancer indications (e.g., skin cancer)40% success
• Q2 2026Publication of clinical study data demonstrating reduced re-excision rates in breast cancer50% success
• Q4 2026Strategic partnership or distribution agreement with a major hospital network35% success